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Advancing Treatment of Pituitary 
Adenomas through Targeted 
Molecular Therapies: The 
Acromegaly and Cushing Disease 
Paradigms
Michael A. Mooney, Elias D. Simon and Andrew S. Little*
Department of Neurosurgery, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
The current treatment of pituitary adenomas requires a balance of conservative man-
agement, surgical resection, and in select tumor types, molecular therapy. Acromegaly 
treatment is an evolving field where our understanding of molecular targets and drug 
therapies has improved treatment options for patients with excess growth hormone 
levels. We highlight the use of molecular therapies in this disease process and advances 
in this field, which may represent a paradigm shift for the future of pituitary adenoma 
treatment.
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inTRODUCTiOn
Pituitary adenomas make up more than 90% of all pituitary tumors and are the second most com-
monly diagnosed non-malignant brain tumors (1). The clinical presentation of patients with pituitary 
adenomas is highly variable and often depends on the endocrinologic function of the tumor, the size 
of the tumor, or a combination of both. Given the increased use of neuroimaging studies over the 
past decade, a significant number of pituitary lesions are incidentally found, and the prevalence of 
pituitary tumors in the general population is estimated to be around 17% (2). The heterogeneity 
of clinical presentations combined with the relatively high prevalence of “incidentalomas” poses a 
diagnostic challenge to providers treating these patients, and multidisciplinary teams consisting of 
endocrinologists, neuro-ophthalmologists, and neurosurgeons have proven essential for delivering 
the highest quality of care.
Distinguishing a functional (i.e., hormone-secreting) from a non-functional adenoma is crucial 
for guiding subsequent treatment strategies. Although surgical resection remains the mainstay of 
therapy for macroadenomas causing compression of neurovascular structures, as well as for many 
functional microadenomas, pharmacotherapy can play a crucial role in adenoma treatment. Recent 
advances in genetic and molecular analysis of pituitary adenomas have provided new insights 
into the growth patterns and secretory functions of these tumors and have allowed for a more 
precise characterization of individual adenomas. These advances have led to the development of 
targeted molecular therapies for several subtypes of pituitary adenoma and the development of a 
Abbreviations: ACTH, adrenocorticotropic hormone; DR, dopamine receptor; GH, growth hormone; IGF, insulin-like growth 
factor; OGTT, oral glucose tolerance test.
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“personalized” approach to pharmacotherapy for some patients 
with adenomas.
Acromegaly is one pituitary disease where recent and ongo-
ing research has changed the standard treatment paradigm. 
Although pharmacotherapy has not replaced surgical resection 
as the mainstay of treatment, exciting advances in targeted 
molecular therapies have developed in recent years. We can 
currently implement individualized treatment options for 
patients with acromegaly, and the potential of this strategy is 
immense as our understanding of the molecular pathology of 
these tumors progresses. We believe that the combined surgi-
cal, targeted pharmacotherapeutic, and radiosurgical approach 
that is employed in acromegaly represents a paradigm that will 
continue to improve the treatment of not only growth hormone 
(GH)-secreting adenomas but also other functional and non-
functional adenomas.
In this review, we highlight the current literature on the diag-
nosis and treatment of acromegaly with an emphasis on current 
targeted molecular therapies. We also review emerging treatment 
paradigms for Cushing disease that parallel this approach, and we 
discuss future directions for this exciting field.
GROwTH HORMOne-SeCReTinG 
ADenOMAS
Overview
Growth hormone-secreting pituitary adenomas manifest as the 
clinical syndrome acromegaly, which is a chronic disorder that 
results in acral overgrowth, cardiovascular disease, insulin resist-
ance, arthritis, and sleep apnea, among other conditions (3). In 
children harboring a GH-secreting adenoma, excess GH produc-
tion before closure of the epiphyseal plates leads to gigantism. 
Given the widespread effects of GH overproduction, as well as the 
often indolent physiologic changes in an individual patient, the 
diagnosis of acromegaly is often delayed. If untreated, acromegaly 
results in significant morbidity and increased rates of mortality 
for these patients (4).
The current diagnosis of acromegaly is dependent upon both 
the oral glucose tolerance test (OGTT) and serum levels of 
insulin-like growth factor-1 (IGF-1). A decline in GH produc-
tion after an oral glucose load is present in normal patients, and 
this decrease is diminished in patients with acromegaly; detailed 
criteria have been established for utilizing this diagnostic tool to 
help identify patients with acromegaly (5). Additionally, serum 
IGF-1 levels are elevated in patients with acromegaly because of 
increased production from the liver. Circulating GH binds GH 
receptors on hepatocytes and activates a signaling cascade, result-
ing in increased in IGF1 transcription, translation, and IGF-1 
secretion (3). IGF-1 levels adequate for diagnosis are dependent 
on sex and age, and established values have been outlined (5–9). 
IGF-1 exerts effects on numerous target tissues throughout the 
body, and stimulation via this growth factor contributes to the 
increased morbidity and mortality encountered in patients with 
acromegaly (4).
Surgical resection is the mainstay of treatment for acromegaly 
caused by a GH-secreting adenoma. However, not all patients 
are candidates for surgery, and not all adenomas are amenable 
to complete resection. Since surgical treatment is not always an 
option, a large role for both pharmacotherapy and stereotactic 
radiosurgery has developed in this population of patients. An 
improved molecular understanding of pituitary adenomas has 
advanced pharmacologic options for acromegaly patients, and 
we hypothesize that this is the start of a paradigm shift in the 
treatment of acromegaly. In this article, we review the literature 
on surgical success rates and targeted molecular therapies in 
acromegaly. Radiosurgery success rates and expert opinions on 
the implementation of this strategy have been reviewed elsewhere 
(10–12).
Surgical Treatment
Surgical success rates in the literature vary widely depending on 
tumor size, the degree of invasion, surgeon experience, adjuvant 
therapies, and definition of success (i.e., laboratory values defined 
as curative). When examining the success of surgery alone, the 
largest series as of 2016 examined 688 patients with acromegaly 
treated at a single center (13). Criteria required to define a cure 
included normalization of basal GH to <2.5 ng/L, suppression of 
GH to <1 ng/L during the OGTT, and IGF-I normal for age and 
sex, which are the current standard definitions for biochemical 
remission. The overall remission rate for all tumors treated via the 
transsphenoidal approach was 57.3% at the 3-month follow-up in 
this study. Of note, success varied widely based on tumor size and 
invasion characteristics, with 75.3% of microadenomas surgically 
in remission versus 41.5% of macroadenomas with parasellar or 
sphenoidal extension. In this series, only two patients with surgi-
cal remission developed recurrent acromegaly within a mean 
follow-up of 10 or more years.
Numerous smaller series in the literature largely support these 
values, with surgical remission rates ranging to 60% (14–20). 
Reported recurrence rates in the literature to date vary widely 
due to the different criteria for biochemical remission and vary-
ing years of follow-up; recurrence rates ranging from 0.4 to 19% 
(7, 13, 17, 21–23) are reported, with one 2012 meta-analysis citing 
a mean 6% recurrence rate within 10 years (20).
Targeted Molecular Therapies
For the subset of acromegaly patients without biochemical remis-
sion after surgery, or for those patients who are unable or unwilling 
to undergo surgery, pharmacotherapy takes on an essential role. 
Pharmacotherapy for acromegaly was first used in the 1970s, and 
our understanding of GH-secreting adenomas has significantly 
advanced since that time (24). With a better understanding of 
the molecular biology of GH-secreting cells, the introduction 
of more targeted therapies has been possible, and we can now 
better tailor pharmacotherapy regimens for individual patients 
with acromegaly.
The population of cells within the anterior pituitary gland 
that secrete GH were identified in the early twentieth century in 
association with acromegaly and became known as somatotroph 
cells (24). Like other cell types of the anterior pituitary gland, 
somatotroph cells typically remain under tight physiologic control 
through positive and negative feedback from the hypothalamus. 
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Somatotroph cells express two classes of receptors that mediate 
negative feedback – dopamine receptors (DRs) and somatostat in 
receptors. Both pathways have been successfully targeted phar-
macologically and with a resultant decrease in GH secretion 
in patients with acromegaly. A third pathway, the GH receptor 
pathway, has also been successfully targeted for acromegaly 
pharmacotherapy. All three pathways are reviewed here.
Dopamine receptors are encoded by five separate genes 
(DRD1–DRD5). However, DRD2 and DRD4 are the two 
genes predominantly expressed in the normal pituitary gland 
(25). DRD2 is strongly expressed in both somatotrophs and 
lactotrophs, and binding of dopamine (or dopamine agonist 
medications) to DRD2 triggers an inhibitory signaling cascade 
to decrease prolactin secretion. DRs were first targeted in the 
1970s with the dopamine agonist bromocriptine; however, the 
dopamine agonist cabergoline has since proven to be more 
effective due to its increased DR2 selectivity and longer half life 
(26, 27). Interestingly, DR2 expression levels in somatotrophs are 
correlated with dopamine agonist response rates both in vitro and 
in  vivo, and analysis of prolactin and DR2 expression patterns 
within GH-secreting adenomas has been proposed as a guide 
for pharmacotherapy strategies in acromegaly patients (28–31). 
Furthermore, dopamine agonists are recommended for adenomas 
that secrete both GH and prolactin if pharmacotherapy is needed 
after surgery because both expression pathways are targeted by 
these agents (32).
Somatostatin receptors are also encoded by five separate genes 
(SSTR1–SSTR5), and the SSTR2 and SSTR5 subtypes make up 
90–95% of receptor expression in GH-secreting adenomas (33). 
SSTR expression is found within normal pituitary cells including 
corticotrophs and lactotrophs, and binding of somatostatin to 
SSTRs triggers a G-protein-mediated signal cascade that inhibits 
secretory function in these cells. The two standard somatostat in 
analogs in use today are octreotide and lanreotide, which 
activate this signaling pathway to inhibit hormone production 
in functional adenomas. There is significant heterogeneity in 
clinical responsiveness to these agents, and recent research sug-
gests this may be due to heterogeneous SSTR subtype expression 
between patients (34, 35). More recently, the somatostatin analog 
pasireotide was developed, which has increased binding affinity 
for SSTR2 and SSTR5 compared to octreotide and lanreotide. 
Pasireotide has shown superior efficacy for biochemical control 
in some studies of patients with acromegaly (36). This drug class 
is one example of how an improved molecular understanding of 
somatotrophs may provide more efficacious treatment options for 
patients with acromegaly; however, further studies are required 
before receptor expression profiles can be used to guide clinical 
practice.
The class of GH-receptor antagonists is the third and final 
example of successful targeted molecular therapy in acromegaly. 
GH receptors are found primarily in the liver and cartilage where 
activation triggers the JAK–STAT (Janus kinase/signal trans-
ducers and activators of transcription) pathway and ultimately 
leads to upregulation in cell proliferation and antiapoptotic 
proteins, including IGF-1 (3). Pegvisomant is currently the only 
GH-receptor antagonist approved by the U.S. Food and Drug 
Administration that is available for treatment of acromegaly, 
and it is a pegylated analog of human GH, which directly 
competes for receptor binding with plasma GH (37). Binding 
of pegvisomant prevents dimerization of the GH-receptor and 
thereby blocks the signaling cascade, resulting in decreased 
IGF-1 production. Of note, this mechanism is significantly 
different from that of the dopamine and somatostatin analogs, 
because it blocks the downstream effects of a GH-secreting 
adenoma, independent of tumor receptor expression patterns 
(3, 38). Use of pegvisomant is typically reserved for patients in 
whom treatment with somatostatin analogs fails or in patients 
with diabetes mellitus (32, 39).
Current and Future Clinical Practice
Complete surgical resection of a GH-secreting adenoma remains 
the first-line treatment option for acromegaly today. Surgical cure 
rates are high, with low morbidity and mortality when surgery is 
performed at a center with an experienced neurosurgical team 
as the first-line treatment for eligible patients. In patients with 
persistent or recurrent disease after surgery, or those unable to 
or unwilling to undergo surgery, pharmacotherapy and stereo-
tactic radiosurgery remain excellent treatment options. Several 
pathways of pharmacotherapy for acromegaly have been evalu-
ated, including use as adjuvant therapy (following surgery), as 
neoadjuvant therapy (before surgery), and as primary therapy 
(in place of surgery). The efficacy and implementation of stereo-
tactic radiosurgery for functional pituitary adenomas have been 
extensively reviewed elsewhere (10–12).
Numerous studies have evaluated the efficacy of pharmaco-
therapy for persistent or recurrent disease after surgical resection, 
and somatostatin analogs are considered first-line therapy for 
these patients (40). It is estimated that approximately 30–60% of 
patients with persistent disease after surgical resection achieve 
biochemical remission with the addition of a somatostatin 
analog (41–44). An additional percentage of patients achieve 
biochemical remission with dopamine agonists, pegvisomant, or 
combination therapy with these agents. Radiological follow-up in 
these patients must be interpreted with caution. Tumor shrinkage 
is often observed with postoperative somatostatin analog treat-
ment, but, this does not reliably correlate with biochemical remis-
sion (42, 45). Notably, some studies have noted correlations in 
somatostatin and dopamine expression patterns in the adenoma 
with treatment response, which may allow for a more individual-
ized approach to pharmacotherapy strategies in these patients in 
the future (2, 29, 30, 34, 35, 46–49). GH and IGF-1 must be closely 
monitored in patients with known residual tumor undergoing 
adjuvant treatment, and treatment strategies for recurrent disease 
must be made on a case-by-case basis.
Neoadjuvant therapy with somatostatin analogs has been 
attempted in patients with large GH-secreting adenomas with 
some success. Preoperative treatment with somatostatin analogs 
was investigated in multiple studies of macroadenomas secret-
ing GH, and this regimen was consistently shown to decrease 
tumor volume and GH secretion levels in patients prior to 
surgery (50). Additionally, short-term biochemical remission 
rates (3–4 months postoperatively) were consistently improved 
with neoadjuvant therapy. However, this effect was not clearly 
FiGURe 1 | venn diagram illustrating the relative impact of antitumor treatments in acromegaly as practiced today and what it might look like in the 
future. Used with permission from Barrow Neurological Institute, Phoenix, Arizona.
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demonstrated for long-term remission rates, and further studies 
on this subject remain to be performed. Although preoperative 
somatostatin analogs may decrease tumor volume, they do not 
convert unresectable, invasive tumors into resectable lesions. We 
believe this may limit the success of this strategy going forward, 
and preoperative somatostatin analogs should be given only to a 
small subset of carefully selected patients.
Since their introduction, the success of monotherapy with 
somatostatin analogs for some patients has been the most impres-
sive contribution of pharmacotherapy for acromegaly. Recent 
studies have demonstrated good biochemical control with such 
treatment (36, 51–53). When interpreting biochemical control 
data, it is important to consider whether the patient population 
was preselected for somatostatin responsiveness and what other 
treatments the patients have received. The published remission 
rates for somatostatin analogs have declined as more experience 
is gained with the drugs because of the increased recognition of 
these two factors. Although most studies to date have focused on 
octreotide or lanreotide monotherapy, we hypothesize that future 
studies investigating new-generation somatostatin analogs, such 
as pasireotide, could demonstrate superior results. Preliminary 
studies with pasireotide show significantly higher rates of bio-
chemical control compared with octreotide (36, 54).
At our institution, we attempt complete resection as the first-
line treatment. In patients with residual disease not amenable 
to further resection (and with elevated GH and IGF-1 levels 
postoperatively), adjuvant somatostatin analog therapy is initi-
ated, and patients are monitored for their biochemical response. 
Concurrent adjuvant radiosurgery with somatostatin analog 
treatment is provided on a case-by-case basis considering the 
location and volume of the residual tumor.
As our molecular understanding of somatotrophs advances 
and drugs are developed to target new sites, the role for phar-
macotherapy in acromegaly will continue to expand. Although 
surgical resection remains the mainstay of treatment today, the 
future likely holds a shift in our treatment paradigm to one 
that emphasizes pharmacotherapy (Figure  1). Personalized 
approaches to pharmacotherapy for acromegaly may emerge 
based on molecular expression profiles of individual patient 
tumors; however, future research on this subject is required before 
it can be used to guide treatment for patients with acromegaly.
OTHeR FUnCTiOnAL ADenOMAS
Cushing Disease
Adrenocorticotropic hormone (ACTH)-secreting pituitary 
adenomas manifest as the clinical syndrome of Cushing disease. 
Excessive secretion of ACTH leads to hypercortisolemia, and 
these patients present with widespread clinical symptoms includ-
ing central obesity, facial plethora, amenorrhea, and skin changes, 
among many others. Surgical resection of the ACTH-secreting 
adenoma is currently the mainstay of treatment for patients 
with Cushing disease. However, as with acromegaly, the role for 
pharmacotherapy in treated Cushing disease is growing. As our 
molecular understanding of this disease progresses, drug devel-
opment continues to produce new treatment options for patients 
with persistent or recurrent disease after surgery, as well as for 
those patients unable or unwilling to undergo surgery.
Today, the rate of postoperative biochemical remission follow-
ing surgical resection of microadenomas is approximately 75% 
while remission of macroadenomas is about 43% (55–57). For the 
remainder of patients and for those who do not undergo surgery, 
the addition of pharmacotherapy plays a crucial role in treatment. 
Pharmacotherapy of Cushing disease targets three main pathways: 
central secretory action at the level of the pituitary, steroidogen-
esis, and end-target action at the glucocorticoid receptor (58). As 
with acromegaly, increasing knowledge of corticotroph receptor 
expression has guided medical treatment options for this disease.
Corticotrophs express high levels of SSTR5 and DRD2, similar 
to the expression seen in somatotrophs (59). Pharmacotherapy 
targets these receptors using somatostatin ligands and dopamine 
agonists, respectively, to decrease ACTH production by corti-
cotroph adenomas. Pasireotide, in particular, has demonstrated 
efficacy in patients with Cushing disease due to its relatively high 
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binding affinity for SSTR5 (60). Phase II and III clinical trials 
utilizing pasireotide in patients who have not undergone surgery 
have demonstrated a significant reduction in urinary free cortisol 
levels, as well as improvement in symptoms of hypercortisolemia 
(61). A large, randomized, double-blind, multicenter, phase III 
study is currently underway to evaluate pasireotide as mono-
therapy for this group of patients. Cabergoline is also used in the 
medical management of Cushing disease by targeting corticotroph 
secretory function. Several trials have demonstrated its efficacy 
both in  vitro and in  vivo (62–64). In non-responders or partial 
responders to a single agent, combination therapy with pasireotide 
and cabergoline, was shown to be effective in decreasing urinary 
free cortisol levels (65). Other somatostatin analogs and dopamine 
agonists (octreotide, lanreotide, and bromocriptine) are not as 
effective in Cushing disease as they are in acromegaly, and these 
agents are not routinely used in clinical practice today.
Ketoconazole and metyrapone are the most widely used ste-
roidogenesis inhibitors prescribed today for refractory Cushing 
syndrome; however, no prospective studies have evaluated these 
agents in Cushing disease, and their use is currently off-label 
(66). Investigations into alternative steroidogenesis targets are 
ongoing and may hold future promise (67). Mifepristone is the 
only current glucocorticoid receptor antagonist available for 
use in Cushing disease, and it is Food and Drug Administration 
approved for treatment of hyperglycemia in Cushing syndrome 
(61). It has demonstrated efficacy in long-term symptom resolu-
tion in a multicenter trial (68); however, its use is contraindicated 
in pregnant women, and it may be associated with adenoma 
enlargement (69). Serial magnetic resonance imaging is war-
ranted to monitor for such enlargement in patients with Cushing 
disease treated with mifepristone.
Although numerous pharmacologic targets exist in Cushing 
disease, medical management has yet to reach the efficacy and 
safety of surgery; transsphenoidal resection remains the treat-
ment of choice for eligible patients with an ACTH-secreting 
adenoma. Similar to acromegaly, an improved understanding of 
the molecular basis of corticotroph cells and end-target receptors 
will continue to spur drug development and improve medical 
treatment options for this challenging disease.
COnCLUSiOn AnD FUTURe DiReCTiOnS
Pituitary adenomas are relatively common tumors, and trans-
sphenoidal resection is a safe and effective treatment option 
for many of these lesions. Surgical resection by an experienced 
pituitary surgeon remains the mainstay of therapy for both acro-
megaly and Cushing disease. However, a significant percentage 
of patients have persistent or recurrent disease after surgery or 
are not surgical candidates. An improved understanding of the 
molecular biology of these diseases has evolved since the mid-
1970s, and targeted molecular therapies that limit the growth, 
secretory function, and end-organ effects of these tumors 
continue to be developed. The greatest success has come with 
the class of somatostatin analogs, and new knowledge regarding 
receptor subtype expression in pituitary adenomas has helped 
guide treatment strategies. Further research into this domain may 
allow for more individualized treatment strategies for patients 
harboring tumors with expression patterns that can be charac-
terized. Although some research has supported this approach 
to date, further studies are required before this paradigm can be 
applied outside of academic pituitary practices. Characterization 
of tumor expression patterns is a challenging task, but we believe 
that targeted pharmacotherapy could approach, and eventually 
surpass, the efficacy of surgical resection for the treatment of 
these lesions.
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